Impact of CYP2C19 polymorphism on residual platelet reactivity in patients with coronary heart disease during antiplatelet therapy
Authors:
- 1 March 2011
- journal article
- research article
- Published by Elsevier in Journal of Cardiology
- Vol. 57 (2) , 194-201
Abstract
No abstract availableKeywords
Funding Information
- Ministry of Education, Culture, Sports, Science and Technology
This publication has 24 references indexed in Scilit:
- Association of platelet responsiveness with clopidogrel metabolism: Role of compliance in the assessment of “resistance”American Heart Journal, 2009
- Antiplatelet Therapy and Stent Thrombosis After Sirolimus-Eluting Stent ImplantationCirculation, 2009
- Early Stent Thrombosis in Patients With Acute Coronary Syndromes Treated With Drug-Eluting and Bare Metal StentsCirculation, 2009
- Variability in Responsiveness to Oral Antiplatelet TherapyThe American Journal of Cardiology, 2009
- Cytochrome P-450 Polymorphisms and Response to ClopidogrelNew England Journal of Medicine, 2009
- Genetic Determinants of Response to Clopidogrel and Cardiovascular EventsNew England Journal of Medicine, 2009
- Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort studyThe Lancet, 2009
- Elevated Plasma Fibrinogen and Diabetes Mellitus Are Associated With Lower Inhibition of Platelet Reactivity With ClopidogrelJACC, 2008
- Cytochrome P450 2C19 681G>A Polymorphism and High On-Clopidogrel Platelet Reactivity Associated With Adverse 1-Year Clinical Outcome of Elective Percutaneous Coronary Intervention With Drug-Eluting or Bare-Metal StentsJACC, 2008
- Multiplex PCR amplification from the CFTR gene using DNA prepared from buccal brushes/swabsHuman Molecular Genetics, 1993